Leukaemia inhibitory factor (LIF) upregulates excitatory non-adrenergic non-cholinergic and maintains cholinergic neural function in tracheal explants

D.A. Knight, A.C. D'Aprile, L.J. Spalding, Roy Goldie, Philip Thompson

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The effect of leukaemia inhibitory factor (LIF) in modulating cholinergic and sensory nerve function was examined using guinea-pig tracheal explants. Specific LIF receptors (LIFR) were immunolocalized to both cholinergic and sensory nerves. Release of SP in culture was not influenced by LIF. Similarly, maximum contraction to carbachol (C-max) was not influenced by LIF. After 3 h, maximum (E-max) eNANC-induced contraction in controls was 32 +/- 2.5% of C-max. In LIF-treated preparations, E-max was enhanced to 50 +/- 4.5% C-max (P <0.05). Cholinergic nerve-induced contractions after 3 h incubation with LIF were similar to control. After 24 h, control E-max was 25 +/- 4.5% C-max (58% smaller than E-max at 3 h). In contrast, in LIF-treated preparations, E-max was 37+2.5% C-max, (24% smaller than at 3 h, P <0.05). This did not appear to be due to the effect of LIF on muscarinic Mt receptor expression or function. Thus LIF appears to differentially influence the function of airway nerves and thus may provide an important link between the immune and neural systems.
Original languageEnglish
Pages (from-to)975-979
JournalBritish Journal of Pharmacology
Volume130
DOIs
Publication statusPublished - 2000

Fingerprint

Leukemia Inhibitory Factor
Cholinergic Agents
Up-Regulation
OSM-LIF Receptors
Carbachol
Muscarinic Receptors
Immune System
Guinea Pigs

Cite this

@article{eb765d527fb7404bbaf74bef50221aba,
title = "Leukaemia inhibitory factor (LIF) upregulates excitatory non-adrenergic non-cholinergic and maintains cholinergic neural function in tracheal explants",
abstract = "The effect of leukaemia inhibitory factor (LIF) in modulating cholinergic and sensory nerve function was examined using guinea-pig tracheal explants. Specific LIF receptors (LIFR) were immunolocalized to both cholinergic and sensory nerves. Release of SP in culture was not influenced by LIF. Similarly, maximum contraction to carbachol (C-max) was not influenced by LIF. After 3 h, maximum (E-max) eNANC-induced contraction in controls was 32 +/- 2.5{\%} of C-max. In LIF-treated preparations, E-max was enhanced to 50 +/- 4.5{\%} C-max (P <0.05). Cholinergic nerve-induced contractions after 3 h incubation with LIF were similar to control. After 24 h, control E-max was 25 +/- 4.5{\%} C-max (58{\%} smaller than E-max at 3 h). In contrast, in LIF-treated preparations, E-max was 37+2.5{\%} C-max, (24{\%} smaller than at 3 h, P <0.05). This did not appear to be due to the effect of LIF on muscarinic Mt receptor expression or function. Thus LIF appears to differentially influence the function of airway nerves and thus may provide an important link between the immune and neural systems.",
author = "D.A. Knight and A.C. D'Aprile and L.J. Spalding and Roy Goldie and Philip Thompson",
year = "2000",
doi = "10.1038/sj.bjp.0703415",
language = "English",
volume = "130",
pages = "975--979",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley-Blackwell",

}

Leukaemia inhibitory factor (LIF) upregulates excitatory non-adrenergic non-cholinergic and maintains cholinergic neural function in tracheal explants. / Knight, D.A.; D'Aprile, A.C.; Spalding, L.J.; Goldie, Roy; Thompson, Philip.

In: British Journal of Pharmacology, Vol. 130, 2000, p. 975-979.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Leukaemia inhibitory factor (LIF) upregulates excitatory non-adrenergic non-cholinergic and maintains cholinergic neural function in tracheal explants

AU - Knight, D.A.

AU - D'Aprile, A.C.

AU - Spalding, L.J.

AU - Goldie, Roy

AU - Thompson, Philip

PY - 2000

Y1 - 2000

N2 - The effect of leukaemia inhibitory factor (LIF) in modulating cholinergic and sensory nerve function was examined using guinea-pig tracheal explants. Specific LIF receptors (LIFR) were immunolocalized to both cholinergic and sensory nerves. Release of SP in culture was not influenced by LIF. Similarly, maximum contraction to carbachol (C-max) was not influenced by LIF. After 3 h, maximum (E-max) eNANC-induced contraction in controls was 32 +/- 2.5% of C-max. In LIF-treated preparations, E-max was enhanced to 50 +/- 4.5% C-max (P <0.05). Cholinergic nerve-induced contractions after 3 h incubation with LIF were similar to control. After 24 h, control E-max was 25 +/- 4.5% C-max (58% smaller than E-max at 3 h). In contrast, in LIF-treated preparations, E-max was 37+2.5% C-max, (24% smaller than at 3 h, P <0.05). This did not appear to be due to the effect of LIF on muscarinic Mt receptor expression or function. Thus LIF appears to differentially influence the function of airway nerves and thus may provide an important link between the immune and neural systems.

AB - The effect of leukaemia inhibitory factor (LIF) in modulating cholinergic and sensory nerve function was examined using guinea-pig tracheal explants. Specific LIF receptors (LIFR) were immunolocalized to both cholinergic and sensory nerves. Release of SP in culture was not influenced by LIF. Similarly, maximum contraction to carbachol (C-max) was not influenced by LIF. After 3 h, maximum (E-max) eNANC-induced contraction in controls was 32 +/- 2.5% of C-max. In LIF-treated preparations, E-max was enhanced to 50 +/- 4.5% C-max (P <0.05). Cholinergic nerve-induced contractions after 3 h incubation with LIF were similar to control. After 24 h, control E-max was 25 +/- 4.5% C-max (58% smaller than E-max at 3 h). In contrast, in LIF-treated preparations, E-max was 37+2.5% C-max, (24% smaller than at 3 h, P <0.05). This did not appear to be due to the effect of LIF on muscarinic Mt receptor expression or function. Thus LIF appears to differentially influence the function of airway nerves and thus may provide an important link between the immune and neural systems.

U2 - 10.1038/sj.bjp.0703415

DO - 10.1038/sj.bjp.0703415

M3 - Article

VL - 130

SP - 975

EP - 979

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

ER -